HKSE - Delayed Quote HKD

AIM Vaccine Co., Ltd. (6660.HK)

3.930
+0.210
+(5.65%)
At close: 4:08:41 PM GMT+8
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 6660.HK

Recent News: 6660.HK

View More
AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through

AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through
PR Newswire 15 days ago
Asian Penny Stocks To Watch In May 2025

Asian Penny Stocks To Watch In May 2025
Simply Wall St. 29 days ago
AIM's Serum-Free Iterative Rabies Vaccine Receives Acceptance for Market Registration; Institutions Predict Significant Valuation Recovery Potential for the Company

AIM's Serum-Free Iterative Rabies Vaccine Receives Acceptance for Market Registration; Institutions Predict Significant Valuation Recovery Potential for the Company
PR Newswire last month
AIM Vaccine reduces losses by nearly 90% in 2024, with the iterative major product series opening up space for explosive growth in performance

AIM Vaccine reduces losses by nearly 90% in 2024, with the iterative major product series opening up space for explosive growth in performance
PR Newswire 2 months ago
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates

AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates
PR Newswire 2 months ago
AIM Vaccine reported a significant reduction in losses for 2024, with several major products set to launch that are expected to drive substantial revenue growth

AIM Vaccine reported a significant reduction in losses for 2024, with several major products set to launch that are expected to drive substantial revenue growth
PR Newswire 2 months ago
AIM Vaccine's Serum-Free Iterative Rabies Vaccine Has Received Production License and Will Submit for Market Registration

AIM Vaccine's Serum-Free Iterative Rabies Vaccine Has Received Production License and Will Submit for Market Registration
PR Newswire 2 months ago
AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines

AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines
PR Newswire 2 months ago
AIM Vaccine's mRNA RSV Vaccine Approved for U.S. Clinical Trials

AIM Vaccine's mRNA RSV Vaccine Approved for U.S. Clinical Trials
PR Newswire 3 months ago
AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.

AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.
PR Newswire 3 months ago
AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside

AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside
PR Newswire 3 months ago
View More

Related Tickers

2315.HK Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
17.980
-0.44%
 
1244.HK 3D MEDICINES
4.210
+1.45%
 
2257.HK Sirnaomics Ltd.
3.810
+6.13%
 
2157.HK Lepu Biopharma Co., Ltd.
4.750
+5.32%
 
2197.HK Clover Biopharmaceuticals, Ltd.
0.232
+3.11%
 
6826.HK Shanghai Haohai Biological Technology Co., Ltd.
26.800
+2.68%
 
9969.HK InnoCare Pharma Limited
11.040
-0.36%
 
2171.HK CARsgen Therapeutics Holdings Limited
21.150
-1.17%
 
2137.HK Brii Biosciences Limited
1.860
+1.09%
 
1877.HK JUNSHI BIO
20.750
+9.21%